Determinants Influencing the Administration of Adjuvant Radiation Therapy in Patients with Locally Advanced Rectal Cancer
-
By
-
Maryam Sherwani
-
Danish Ali
-
Hanjoo Lee
-
Alexander T. Hawkins
-
Aimal Khan
-
September 6, 2026
Clinical Scorecard: Determinants Influencing the Administration of Adjuvant Radiation Therapy in Patients with Locally Advanced Rectal Cancer
At a Glance
| Category | Detail |
|---|
| Condition | Locally Advanced Rectal Cancer (LARC) |
| Key Mechanisms | Adjuvant chemoradiation is used primarily for incidental nodal disease or pathologic upstaging after surgery. |
| Target Population | Adults with primary rectal adenocarcinoma diagnosed from 2015 through 2022. |
| Care Setting | Retrospective cohort study utilizing data from the National Cancer Database (NCDB). |
Key Highlights
- Adjuvant RT is less common than neoadjuvant RT, with only 6.9% of patients receiving it.
- Neoadjuvant RT has been shown to improve local control and sphincter preservation.
- Factors influencing adjuvant RT use include sociodemographic determinants.
Guideline-Based Recommendations
Diagnosis
- LARC is defined as TNM stage II–III rectal cancer.
Management
- Neoadjuvant chemoradiation is the standard of care for LARC.
Monitoring & Follow-up
- Assess patient demographics, tumor stage, and treatment modalities.
Risks
- Adjuvant RT may lead to greater overall toxicity and complications.
Patient & Prescribing Data
Patients with locally advanced rectal cancer (LARC) who underwent surgery.
Adjuvant RT is used selectively, often in cases of pathologic upstaging.
Clinical Best Practices
- Utilize neoadjuvant RT for improved outcomes in LARC.
- Consider patient sociodemographics when determining treatment plans.
Related Resources & Content
